Evidence map›Paper›PMID 35866619›Full record

ArticleEuropean journal of cancer care2022

Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attended.

Amalia Martinez, Laetitia Daubisse-Marliac, Jean-Louis Lacaze, Elvire Pons-Tostivint, Eric Bauvin, Cyrille Delpierre, Pascale Grosclaude, Sébastien Lamy, EvaSein Group

Abstract read
In one paragraph

Article in European journal of cancer care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amalia MartinezCERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Laetitia Daubisse-MarliacCERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Jean-Louis LacazeDepartment of Medical Oncology, Claudius Regaud Institute, IUCT-Oncopole, Toulouse, France.
Elvire Pons-TostivintThoracic Oncology Unit, Nantes University Hospital, Nantes, France.
Eric BauvinCERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Cyrille DelpierreCERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Pascale GrosclaudeCERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.
Sébastien LamyCERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France.ORCID https://orcid.org/0000-0003-3886-1968
EvaSein Group

Funding

Institut National Du Cancer
6 · The paper itself

Abstract

objectivesWe studied both the independent and combined effects of the places of biopsy and treatment on the treatment time interval based on a population-based study.

methodsWe analysed the proportion of patients having a treatment time interval higher than the EUSOMA recommendation of 6 weeks, as a function of the number and the type of care centres the patients attended, from a French population-based regional cohort of women treated in 2015 for an incident invasive non-metastatic cancer (n = 505).

resultsAbout 33% [95% CI: 27; 38] of patients had a treatment time interval higher than 6 weeks. About 48% of the patients underwent their biopsy and their initial treatment in the different centres. Results from multivariable analyses supported the impact of the type and number of centres attended on the proportion of time intervals over 6 weeks. This proportion was higher among patients with biopsy and treatment in different centres and among patients treated in a university hospital.

conclusionWe pointed out the independent impact of the type and the number of care centres the patients attended, from biopsy to first treatment, on the treatment time interval, which is a well-known prognosis factor.

Indexed as

Breast NeoplasmsBiopsyFemaleHumansbreast cancerplace of careplace of diagnosispopulation-based studytreatment time interval

Identifiers

PMID35866619
PMCPMC9786268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.